2009∼2018년 혈액배양으로부터 분리된 Candida 균종의 항진균제 감수성의 경향 = Trends of Antifungal Agent Susceptibility of Candida Strains Isolated from Blood Cultures in 2009∼2018

다국어 초록 (Multilingual Abstract)

Candida is one of the most common causes of bloodstream infections and a leading cause of morbidity and mortality among hospitalized patients. The purpose of this study was to provide important information for formulating empirical treatment plans for candidemia by investigating the antifungal resistance rate of Candida. Among the Candida strains (973 cases) isolated from blood culture tests at the S hospital in 2009∼2018, 4.7% (N=44) comprising the Candida spp. (932 strains) showed resistance to fluconazole. The resistant strains included C. albicans, C. parapsilosis, C. tropicalis, and C. glabrata. In addition Candida spp. (947 strains) showed resistance to amphotericin B (N=6, 0.6%), flucytosine (N=23, 2.4%) and voriconazole (N=24, 3.1%). C. albicans was resistant to fluconazole (N=23, 6.9%) and voriconazole (N=21, 6.0%), The statistical analysis showed that C. albicans and non-albicans Candida species were resistant to fluconazole (P=0.039) and voriconazole (P＜0.001). A monitoring system to understand the rate of candidiasis infections in a hospital setting is required. It is also important to make the right choice of the antifungal agent based on drug susceptibility patterns. Therefore, an infection surveillance policy that tracks Candida resistance through regular antifungal susceptibility tests is necessary.

국문 초록 (Abstract)

혈류 감염(BSI)의 주요 원인균의 하나로 입원환자에서 이환율과 사망률을 높이는 칸디다의 항진균제 내성률을 조사하여 칸디다 혈증(candidemia)의 경험적 치료 방침에 중요한 정보를 제공하고자 한다. 2009∼2018년 S병원의 혈액배양 검사에서 분리된 Candida 균주(973건) 중 Candida spp. (932 균주)에 대한 fluconazole 감수성 시험결과에서 4.7% (N=44)가 내성(resistant, R)을 보였고 C. albicans, C. parapsilosis, C. tropicalis, C. glabrata에서 내성 균주를 확인하였다. 또한, Candida spp. (947 균주)의 amphotericin B에 대한 감수성 결과에서는 내성(N=6, 0.6%)이 나타났고, 전체 Candida spp. (973 균주)에 대한 flucytosine 감수성 시험에서는 내성(N=23, 2.4%)을 보였다. Candida spp. (768 균주)의 voriconazole에 대한 감수성 시험에서는 내성(N=24, 3.1%)을 보였다. C. albicans는 fluconazole (N=23, 6.9%), voriconazole (N=21, 6.0%)이 내성이고 통계학적으로 C. albicans과 non-albicans Candida species은 fluconazole (P=0.039), voriconazole (P＜0.001)로 나타났다. 칸디다 혈증의 감염률을 이해하고 예방하기 위한 감시 시스템이 요구되고 항진균제의 적절한 투여와 치료가 요구된다. 따라서 항진균제 감수성 결과의 모니터링을 통한 칸디다의 내성을 추적하는 감염감시활동 정책이 필요할 것으로 사료된다.

참고문헌 (Reference)

• 1 채명종 ; 신종희 ; 조덕 ; 기승정 ; 김수현 ; 신명근 ; 신동현 ; 정숙안 ; 서순팔 ; 양동욱, "최근 8년간 혈액에서 분리된 Candida 균종과 항진균제 감수성" 대한진단검사의학회 23 (23): 329-335, 2003
• 2 김재수 ; 공소영 ; 김종완 ; 임인수 ; 김가연, "최근 8년간 혈액배양에서 분리된 미생물의 항균제 감수성 양상: 2010∼2017" 대한임상검사과학회 51 (51): 155-163, 2019
• 3 Hesstvedt L, "Twenty-two years of candidaemia surveillance : results from a Norwegian national study" 21 : 938-945, 2015
• 4 Vallabhaneni S, "The global burden of fungal diseases" 30 : 1-11, 2016
• 5 Lackner M, "Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species" 56 : 2635-2642, 2012
• 6 Colombo AL, "Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients : an analysis of five multicenter studies sequentially conducted over a 9-year period" 40 : 1489-1498, 2014
• 7 Healey KR, "Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance" 7 : 11128-, 2016
• 8 St-Germain G, "Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites : results of a 2-year(1996 to 1998)multicenter surveillance study in Quebec, Canada" 39 : 949-953, 2001
• 9 Horn DL, "Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections" 59 : 407-414, 2007
• 10 Rex JH, "Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America" 30 : 662-678, 2000
• 11 Goto M, "Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe" 19 : 501-509, 2013
• 12 WisplinghoffH, "Nosocomial bloodstream infections in US hospitals : analysis of 24, 179 cases from a prospective nationwide surveillance study" 39 : 309-317, 2004
• 13 Pfaller MA, "International surveillance of bloodstream infections due to Candida species : frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and Voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program" 39 : 3254-3259, 2001
• 14 Chakrabarti A, "Incidence, characteristics and outcome of ICU-acquired candidemia in India" 41 : 285-295, 2015
• 15 Vallabhaneni S, "Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections : data from a large multisite population-based candidemia surveillance program, 2008~2014" 2 : ofv163-, 2015
• 16 Cho EJ, "Emergence of multiple resistance profiles involving azoles, echinocandins and Amphotericin B in Candida glabrata isolates from a neutropenia patient with prolonged fungaemia" 70 : 1268-1270, 2015
• 17 Cleveland AA, "Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013 : results from population-based surveillance" 10 : e0120452-, 2015
• 18 Trecarichi EM, "Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies : an Italian multicentre prospective survey" 21 : 337-343, 2015
• 19 Pappas PG, "Clinical practice guideline for the management of candidiasis : 2016 update by the Infectious Diseases Society of America" 62 : e1-e50, 2016
• 20 López Dupla M, "Clinical characterization of breakthrough bacteraemia : a survey of 392 episodes" 258 : 172-180, 2005
• 21 Khan Z, "Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a12-year period in Kuwait Ziauddin Khan" 14 : e0216250-, 2019
• 22 Antinori S, "Candidemia and invasive candidiasis in adults : A narrative review" 34 : 21-28, 2016
• 23 Kett DH, "Candida bloodstream infections in intensive care units : analysis of the extended prevalence of infection in intensive care unit study" 39 : 665-670, 2011
• 24 World Health Organization, "Antimicrobial resistance global report on surveillance 2014"
• 25 WHO, "Antimicrobial Resistance: Global Report on Surveillance"
• 26 Rex JH, "A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects" 36 : 1221-1228, 2003
• 27 Bassetti M, "A multicenter study of septic shock due to candidemia : outcomes and predictors of mortality" 40 : 839-845, 2014
• 28 Rodriguez L, "A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru : Species distribution, antifungal resistance and clinical outcomes" 12 : e0175172-, 2017